Vitrolife AB Fourth quarter and full year report, 2024: A strong finish to the year
Vitrolife AB reported strong Q4 2024 results with sales reaching SEK 959 million, up 6% in local currencies. Regional performance showed growth of 10% in EMEA and 9% in Americas, while APAC declined 2%. By business area, Consumables grew 12%, Technologies 9%, while Genetics remained flat.
The company's gross margin improved to 61.1% from 56.9%, while EBITDA increased to SEK 337 million with a margin of 35.1%. Net income recovered significantly to SEK 139 million from a loss of SEK 4,179 million, resulting in earnings per share of SEK 1.03.
For full-year 2024, sales reached SEK 3,609 million, showing 4% growth in local currencies. The Board proposed a dividend of SEK 1.10 per share, up from SEK 1.00 in the previous year. Operating cash flow for the year improved to SEK 907 million from SEK 757 million.
Vitrolife AB ha riportato risultati solidi per il quarto trimestre del 2024, con vendite che hanno raggiunto i 959 milioni di SEK, registrando un aumento del 6% in valute locali. Le performance regionali hanno mostrato una crescita del 10% in EMEA e del 9% nelle Americhe, mentre l'APAC ha registrato un calo del 2%. Per area di business, i consumabili sono cresciuti del 12%, le tecnologie del 9%, mentre la genetica è rimasta stabile.
Il margine lordo dell'azienda è migliorato al 61,1% rispetto al 56,9%, mentre l'EBITDA è aumentato a 337 milioni di SEK con un margine del 35,1%. Il reddito netto è aumentato significativamente a 139 milioni di SEK, rispetto a una perdita di 4.179 milioni di SEK, portando a un utile per azione di 1,03 SEK.
Per l'intero anno 2024, le vendite hanno raggiunto i 3.609 milioni di SEK, mostrando una crescita del 4% in valute locali. Il Consiglio ha proposto un dividendo di 1,10 SEK per azione, rispetto a 1,00 SEK dell'anno precedente. Il flusso di cassa operativo per l'anno è migliorato a 907 milioni di SEK rispetto a 757 milioni di SEK.
Vitrolife AB reportó resultados fuertes en el cuarto trimestre de 2024, con ventas alcanzando 959 millones de SEK, lo que representa un aumento del 6% en monedas locales. El rendimiento regional mostró un crecimiento del 10% en EMEA y del 9% en América, mientras que APAC disminuyó un 2%. Por área de negocio, los consumibles crecieron un 12%, las tecnologías un 9%, mientras que la genética se mantuvo plana.
El margen bruto de la empresa mejoró al 61,1% desde el 56,9%, mientras que el EBITDA aumentó a 337 millones de SEK con un margen del 35,1%. El ingreso neto se recuperó significativamente a 139 millones de SEK desde una pérdida de 4.179 millones de SEK, lo que resultó en ganancias por acción de 1,03 SEK.
Para todo el año 2024, las ventas alcanzaron 3.609 millones de SEK, mostrando un crecimiento del 4% en monedas locales. La Junta propuso un dividendo de 1,10 SEK por acción, frente a 1,00 SEK del año anterior. El flujo de caja operativo para el año mejoró a 907 millones de SEK desde 757 millones de SEK.
Vitrolife AB는 2024년 4분기 강력한 실적을 발표했으며, 매출은 959 백만 SEK에 달하며, 현지 통화 기준 6% 증가했습니다. 지역별 성과는 EMEA에서 10%, 아메리카에서 9% 증가했지만, APAC에서는 2% 감소했습니다. 사업 분야별로는 소모품이 12% 성장했으며, 기술이 9% 증가했으나 유전학은 변동이 없었습니다.
회사의 총 마진은 56.9%에서 61.1%로 개선되었고, EBITDA는 337 백만 SEK로 증가하며 35.1%의 마진을 기록했습니다. 순이익은 4,179 백만 SEK의 손실에서 139 백만 SEK로 크게 회복되어 주당 수익이 1.03 SEK에 달했습니다.
2024년 전체 연도에 대해 매출은 3,609 백만 SEK에 도달하며 현지 통화 기준 4% 성장했습니다. 이사회는 작년의 1.00 SEK에서 증가한 1.10 SEK의 배당금을 제안했습니다. 연간 운영 현금 흐름은 757 백만 SEK에서 907 백만 SEK로 개선되었습니다.
Vitrolife AB a annoncé des résultats solides pour le quatrième trimestre 2024, avec des ventes atteignant 959 millions de SEK, en hausse de 6% en devises locales. La performance régionale a montré une croissance de 10% en EMEA et de 9% en Amérique, tandis que l'APAC a diminué de 2%. Par secteur d'activité, les consommables ont augmenté de 12%, les technologies de 9%, tandis que la génétique est restée stable.
La marge brute de l'entreprise s'est améliorée à 61,1% contre 56,9%, tandis que l'EBITDA a augmenté à 337 millions de SEK avec une marge de 35,1%. Le revenu net a considérablement récupéré à 139 millions de SEK, contre une perte de 4,179 millions de SEK, entraînant un bénéfice par action de 1,03 SEK.
Pour l'année entière 2024, les ventes ont atteint 3.609 millions de SEK, enregistrant une croissance de 4% en devises locales. Le Conseil a proposé un dividende de 1,10 SEK par action, contre 1,00 SEK l'année précédente. Le flux de trésorerie d'exploitation pour l'année s'est amélioré à 907 millions de SEK, contre 757 millions de SEK.
Vitrolife AB berichtete für das vierte Quartal 2024 von starken Ergebnissen, mit einem Umsatz von 959 Millionen SEK, was einem Anstieg von 6% in lokalen Währungen entspricht. Die regionale Leistung zeigte ein Wachstum von 10% in EMEA und 9% in Amerika, während APAC um 2% zurückging. Nach Geschäftsfeld wuchsen die Verbrauchsmaterialien um 12%, die Technologien um 9%, während die Genetik stabil blieb.
Die Bruttomarge des Unternehmens verbesserte sich von 56,9% auf 61,1%, während das EBITDA auf 337 Millionen SEK mit einer Marge von 35,1% stieg. Der Nettogewinn erholte sich signifikant auf 139 Millionen SEK von einem Verlust von 4.179 Millionen SEK und führte zu einem Gewinn pro Aktie von 1,03 SEK.
Für das Gesamtjahr 2024 erreichte der Umsatz 3.609 Millionen SEK, was einem Wachstum von 4% in lokalen Währungen entspricht. Der Vorstand schlug eine Dividende von 1,10 SEK pro Aktie vor, gegenüber 1,00 SEK im Vorjahr. Der operative Cashflow für das Jahr verbesserte sich von 757 Millionen SEK auf 907 Millionen SEK.
- Q4 sales increased 6% to SEK 959 million
- Q4 gross margin improved to 61.1% from 56.9%
- Q4 EBITDA margin increased to 35.1% from 32.5%
- Operating cash flow improved to SEK 907 million from SEK 757 million
- Proposed dividend increased to SEK 1.10 from SEK 1.00 per share
- Strong recovery in net income from previous year's losses
- APAC region showed -2% growth in Q4
- Genetics business area showed 0% growth in Q4
- Genetics segment declined -5% for full year
- Sales of
SEK 959 (904) million, an increase of6% in local currencies and6% in SEK. - Sales per region, in local currencies was +
10% in EMEA, +9% inAmericas and -2% in APAC. - Sales per business area, in local currencies was +
12% in Consumables, +9% in Technologies and0% in Genetics. - Gross margin increased to
61.1% (56.9). - Operating income before depreciation and amortisation (EBITDA) increased to
SEK 337 (294) million, giving an EBITDA margin of35.1% (32.5). - Operating cash flow increased to
SEK 268 million (171). - Net income was
SEK 139 (-4,179) million, resulting in earnings per share before dilution ofSEK 1.03 (-30.86) and after dilution ofSEK 1.02 (-30.86). - Helena Wennerström was appointed acting CFO of Vitrolife AB (publ) effective 3 December 2024.
Full year
- Sales of
SEK 3,609 (3,512) million, an increase of4% in local currencies and3% in SEK. - Sales per region, in local currencies was +
7% in EMEA, +1% inAmericas and +5% in APAC. - Sales per business area, in local currencies was +
10% in Consumables, +16% in Technologies and -5% in Genetics. - Gross margin increased to
59.3% (56.3). - Operating income before depreciation and amortisation (EBITDA) increased to
SEK 1,225 (1,136) million, giving an EBITDA margin of34.0% (32.3). - Operating cash flow increased to
SEK 907 million (757). - Net income was
SEK 514 (-3,851) million, resulting in earnings per share before dilution ofSEK 3.79 (-28.44) and after dilution ofSEK 3.78 (-28.44).
Dividend
- The Board to propose to the Annual General Meeting a dividend of
SEK 149 (135) million, corresponding toSEK 1.10 (1.00) per share.
VITROLIFE AB (publ)
Bronwyn Brophy O´Connor,
CEO
The information was submitted for publication, through the agency of the contact persons set out above, at 30-01-2025 08:00 CET.
Contact:
Helena Wennerström, acting CFO, phone: +4670 822 80 86
This is a translation of the Swedish version of the press release. When in doubt, the Swedish wording prevails.
This information was brought to you by Cision http://news.cision.com.
The following files are available for download:
Interim report Q4, 2024: A strong finish to the year |
View original content:https://www.prnewswire.com/news-releases/vitrolife-ab-fourth-quarter-and-full-year-report-2024-a-strong-finish-to-the-year-302364243.html
SOURCE Vitrolife AB (publ)
FAQ
What was Vitrolife's (VTRLY) Q4 2024 sales performance?
How did Vitrolife's (VTRLY) regional sales perform in Q4 2024?
What is Vitrolife's (VTRLY) dividend proposal for 2024?
How did Vitrolife's (VTRLY) business segments perform in Q4 2024?
What was Vitrolife's (VTRLY) EBITDA margin in Q4 2024?
